For Healthcare Professionals

FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer


About the study

The goal of this research is to test the accuracy of PET/MRI imaging with 18F-fluorofuranylnorprogesterone (FFNP) for measuring progesterone receptor (PR) expression in patients with invasive breast cancer. The hypothesis is that FFNP SUVmax from PET/MRI will correlate well against the semi-quantitative PR immunohistochemistry score.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Women 18 years of age or older
  2. Diagnosis of biopsy-proven invasive breast cancer measuring at least 1.0 cm in diameter by any imaging modality
  3. Biopsy-proven PR-positive (N=23) or PR-negative (N=5) invasive breast cancer
  4. Undergoing diagnostic breast MRI ordered by the referring clinician for staging and extent of disease


Exclusion Criteria:

  1. Inability or unwillingness to provide informed consent to the study
  2. Participants currently undergoing neoadjuvant chemotherapy/endocrine therapy or those who have received chemotherapy/endocrine therapy within 6 months prior to the MRI
  3. Participants who have had neoadjuvant chemotherapy/endocrine therapy, surgical intervention, or radiation for the current biopsy-proven malignancy
  4. Participants with breast expanders
  5. Participants who are or might be pregnant or lactating
  6. Participant girth exceeds the bore of the PET/MRI scanner
  7. Participants with a contraindication to gadolinium based contrast agents, including allergy or impaired renal function (per University of Wisconsin Health Guidelines)
  8. Participants with a history of allergic reaction attributable to compounds of similar chemical or biologic composition to FFNP
  9. Participants in liver failure as judged by the patient's physician
  10. Participants with standard contraindications to MRI, including claustrophobia and metallic implants incompatible with MRI

Participants requiring intravenous (IV) conscious sedation for imaging are not eligible; participants requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met:

  1. The subject has their own prescription for the medication
  2. The informed consent process is conducted prior to the self-administration of this medication
  3. They come to the research visit with a driver
  4. Participants unable to lie prone for 30 minutes for imaging
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Phone iconCall 608-262-7269Email iconEmail Study Center

Study’s details


Invasive Breast Cancer

Age (in years)



Phase 2

Participants needed


Est. Completion Date

Dec 31, 2024

Treatment type



University of Wisconsin, Madison identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.